ImmunityBio (IBRX) Total Non-Current Liabilities (2014 - 2026)

ImmunityBio (IBRX) has reported Total Non-Current Liabilities for 13 consecutive years, with $1.5 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 71.18% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 71.18% YoY), while the FY2025 annual figure was $1.0 billion, up 14.96% from the prior year.
• Total Non-Current Liabilities grew to $1.5 billion in Q1 2026 per IBRX's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.5 billion in Q1 2026 and bottomed at $726.9 million in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $955.6 million across 5 years, with a median of $908.6 million in 2023.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 93.69% — and 2024, when it declined 20.06%.
• ImmunityBio's Total Non-Current Liabilities stood at $790.5 million in 2022, then jumped by 37.79% to $1.1 billion in 2023, then slipped by 20.06% to $870.7 million in 2024, then grew by 14.96% to $1.0 billion in 2025, then soared by 51.37% to $1.5 billion in 2026.
• Business Quant data shows IBRX's Total Non-Current Liabilities at $1.5 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.